Clinical Trial Update: A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SHR-1210 with Famitinib and chemotherapy in non-squamous non-small-cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Famitinib (Famitinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non-squamous Non-small-cell Lung Cancer | Phase 3 | Status: TERMINATED